作者
Gilles Montalescot, Leonardo Bolognese, Dariusz Dudek, Patrick Goldstein, Christian Hamm, Jean-Francois Tanguay, Jurrien M Ten Berg, Debra L Miller, Timothy M Costigan, Jochen Goedicke, Johanne Silvain, Paolo Angioli, Jacek Legutko, Margit Niethammer, Zuzana Motovska, Joseph A Jakubowski, Guillaume Cayla, Luigi Oltrona Visconti, Eric Vicaut, Petr Widimsky
发表日期
2013/9/12
期刊
New England Journal of Medicine
卷号
369
期号
11
页码范围
999-1010
出版商
Massachusetts Medical Society
简介
Background
Although P2Y12 antagonists are effective in patients with non–ST-segment elevation (NSTE) acute coronary syndromes, the effect of the timing of administration — before or after coronary angiography — is not known. We evaluated the effect of administering the P2Y12 antagonist prasugrel at the time of diagnosis versus administering it after the coronary angiography if percutaneous coronary intervention (PCI) was indicated.
Methods
We enrolled 4033 patients with NSTE acute coronary syndromes and a positive troponin level who were scheduled to undergo coronary angiography within 2 to 48 hours after randomization. Patients were randomly assigned to receive prasugrel (a 30-mg loading dose) before the angiography (pretreatment group) or placebo (control group). When PCI was indicated, an additional 30 mg of prasugrel was given in the pretreatment group at the time of PCI and 60 mg of …
学术搜索中的文章
G Montalescot, L Bolognese, D Dudek, P Goldstein… - New England Journal of Medicine, 2013